

Press Release

Japan grants Patent for ChromaCon's CaptureSMB® Process

Zurich, November 18th, 2014

Zurich, Switzerland, November 18, 2014 – ChromaCon adds CaptureSMB® patent in a major Asian market to its growing patent portfolio.

The Japan Patent Office granted ChromaCon full protection of its CaptureSMB® process technology in November 2014.

The CaptureSMB® process is a novel chromatographic process principle based on a twin column configuration, offering significant advantages for the capture of monoclonal antibodies and IgG plasma proteins. As Protein A is expensive, applying CaptureSMB® saves 40-60% of consumables, amounting to several million USD per annum for a standard monoclonal antibody process in commercial manufacturing. Furthermore it allows more efficient processing, and consequently significantly faster project turnover in clinical trial manufacturing. The CaptureSMB® process uses ChromIQ® software, the same operating system as ChromaCon's successful Contichrom® equipment line.

In October 2014 the CaptureSMB® process was licensed to LEWA – Nikkiso (key facilities in Leonberg, Germany, Devens, MA USA and Tokyo, Japan) for implementation on LEWA's EcoPrime platform of GMP scale-up systems worldwide.

The CaptureSMB® patent application was classed as highly innovative and fast-tracked through the Patent Prosecution Highway, a route set up to allow such patents to be evaluated and approved faster.

Commenting on this favorable decision for ChromaCon, CEO Dr. Michael Bavand noted: "We are pleased to extend our patent portfolio in process chromatography with the granting of the CaptureSMB® patent in Japan. It allows us and our licensees to offer and implement superior equipment and process solutions for cyclic and continuous processes."

To find out more about ChromaCon browse our website www.chromacon.ch

ChromaCon contact

Dr. Claire Kennedy, Business Director, phone +41-44452010, claire.kennedy@chromacon.com

Dr. Michael Bavand, CEO, phone +41 44 4452013, michael.bavand@chromacon.com

About ChromaCon

ChromaCon AG is a private Life Science Tool company located in Zürich, Switzerland, providing novel, best-in-class chromatographic process solutions to the biopharmaceutical industry. ChromaCon has developed and patented process principles, process control, equipment designs

and operating software for cyclic and continuous chromatography, providing significant CAPEX and OPEX cost savings and enabling scalable chromatographic solutions for large scale purification applications. Its Contichrom[®] entry-stage equipment is co-marketed worldwide with its partner Knauer (Germany). ChromaCon has provided global licenses for its process technologies to LEWA for implementation into scale-up systems. In addition, ChromaCon develops and markets affinity purification solutions for column and membrane chromatography applications and tools for site-specific protein conjugation.